By Fineline Cube Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the ≥4 mg/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.
Clinical Trial Results
| Dose Group | Patients Evaluated | Partial Responses | ORR | DCR | Notable NSCLC Responses |
|---|---|---|---|---|---|
| ≥4 mg/kg (combined) | 9 | 4 | 44.4% | 100% | Multiple significant tumor reductions |
| 5.3 mg/kg | 1 NSCLC patient (2 prior lines) | 1 | 100% | 100% | 55.2% target lesion reduction |
| 4.0 mg/kg | 2 NSCLC patients (≥3 prior lines) | 2 | 100% | 100% | 30.4% and 48.1% target lesion reductions |
Study Design & Safety Profile
- Trial Identifier: NCT07043751
- Patient Population: 26 patients with advanced solid tumors
- Dose Escalation: 0.8 mg/kg → 6.6 mg/kg across five dose levels
- Safety Milestone: No dose-limiting toxicities (DLTs) observed through maximum tested dose
- Treatment-Related Adverse Events (TRAEs):
- Grade 3 TRAEs: 21.7% (5/23 patients with ≥21 days follow-up)
- Grade ≥4 TRAEs: 0% in overall population
- Pulmonary Safety: No interstitial lung disease (ILD) reported, addressing key concern with EGFR-targeting agents
Drug Profile & Competitive Differentiation
- Molecule: TQB6411 – EGFR/c-MET bispecific antibody-drug conjugate (ADC)
- Target Rationale: Dual targeting of EGFR and c-MET pathways addresses resistance mechanisms in solid tumors
- Innovative Design: c-MET-biased affinity reduces development risks while creating differentiated competitive advantage
- Platform Validation: Leverages well-established target combination with novel bispecific ADC format
- Development Status: Category 1 new drug candidate (first-in-class designation in China)
Strategic Clinical Implications
The Phase I data reveals several critical advantages for TQB6411:
- Heavily Pretreated Population: Demonstrates efficacy in patients with 2–3+ prior therapy lines, addressing significant unmet need
- NSCLC Focus: Strong activity in non-small cell lung cancer, where EGFR/c-MET co-expression drives resistance
- Safety Leadership: Absence of ILD and low grade 3+ toxicity rates differentiate from existing EGFR inhibitors
- Dose Optimization: Maximum tolerated dose not reached at 6.6 mg/kg, suggesting potential for further dose escalation
“This first-in-human data validates our c-MET-biased bispecific ADC approach,” said Dr. Wang Li, Chief Executive Officer of CTTQ. “The combination of robust efficacy in heavily pretreated patients with an exceptionally clean safety profile, particularly the absence of interstitial lung disease, positions TQB6411 as a promising candidate for further development in EGFR/c-MET co-expressing solid tumors.”
Market Opportunity & Commercial Outlook
The results position TQB6411 to address substantial markets in oncology:
- Target Population: EGFR/c-MET co-expressing tumors represent significant subsets of NSCLC, gastric, and other solid tumors
- Competitive Landscape: First bispecific ADC targeting this combination with clinical proof-of-concept
- Global Potential: Data supports international regulatory filings and partnership opportunities
- Revenue Projection: Analysts estimate peak annual sales potential of $800 million–$1.2 billion if Phase II/III confirms efficacy
Industry analysts view the 44% ORR in heavily pretreated patients as highly competitive, particularly given the favorable safety profile that could enable combination strategies and broader patient eligibility.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for TQB6411. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech